Background: Apixaban is a direct oral anticoagulant (DOAC) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). Other DOACs require renal dose adjustments based solely on creatinine clearance. Apixaban differs in that its dose adjustments are more complex, potentially leading to prescribing errors. Objective: To determine if adherence to Food and Drug Administration (FDA)-approved dosing for apixaban is maintained in hospitalized patients with NVAF. Methods: Patients ≥18 years old with NVAF who received apixaban during admission to 1 of 3 hospitals were evaluated. The primary outcome was to determine if providers order apixaban in accordance with FDA-approved dosages. Secondary outcomes included determining if pharmacist review increased the number of orders in accordance with FDA-approved dosing, which of the 3 criteria (age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) were met in patients receiving off-label dosing, and the rationale for off-label prescribing. Results: A total of 556 patients met inclusion criteria. Apixaban was dosed according to FDA labeling by providers in 83.4% (n = 464) of orders. After pharmacist review, 87.0% (n = 484) of orders were at the approved dose, 12.2% (n = 68) were underdosed, and 0.7% (n = 4) were overdosed. Most patients who were underdosed met only 1 dose reduction criterion-most commonly age ≥80 years (56.0%). Reasons for off-label dosing included home dose continuation (39.0%), history of or perceived bleeding risk (30.5%), or unspecified/other (30.5%). Conclusions: The majority of apixaban orders for NVAF were based on FDA-approved dosages after provider entry and pharmacist review.
Introduction
Renal drug clearance is the most common pathway for drug elimination, and most renally cleared medications that require dose adjustments are adjusted based on creatinine clearance (CrCl). 1 CrCl is the pivotal parameter dictating dose adjustment for most direct oral anticoagulants (DOACs). However, apixaban has a unique and more complex dose adjustment recommendation when used specifically for the prevention of thromboembolism in nonvalvular atrial fibrillation (NVAF). US Food and Drug Administration (FDA)-approved dosing for apixaban in NVAF is 5 mg twice daily (BID). A dose reduction to 2.5 mg BID is recommended in patients with ≥2 of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine (SCr) ≥1.5 mg/dL. 2 Whereas practitioners more commonly encounter medication reductions in patients with low CrCl, they may be less accustomed to incorporating body weight and age into dose adjustment considerations. The uncommonality of a 3-pronged adjustment criterion could foreseeably potentiate off-label dosing. One study by Nguyen et al 3 evaluating apixaban prescription records written by cardiologists in the United States over a 1-year period found that 20.8% of all apixaban prescriptions for NVAF were for a reduced dose. This rate of realworld reduced dose prescribing is considerably higher than the 4.7% seen in ARISTOTLE. 3, 4 In contrast, a similar rate of reduced-dose rivaroxaban prescriptions (21.7%) was observed by Nguyen et al 3 compared with ROCKET-AF (21.1%). 5 The contrast between clinical trials and practical prescribing patterns suggest that the unique dose adjustment criteria for apixaban has led to more underdosing in clinical practice.
A retrospective study of patients taking DOACs for any indication demonstrated that only 43.3% of prescriptions for reduced dosing were consistent with FDA-approved dosing recommendations. 6 However, a more recent study looking at all DOAC dosing orders in NVAF demonstrated that 87.0% of orders were aligned with package insert recommendations. 7 The results of these studies suggest that the complexity of adjustment may significantly influence approved apixaban use and may be inconsistent across institutions. Additionally, both these studies assessed the outpatient sector, a practice area with less acuity of illness and lab monitoring. To our knowledge no investigation has been conducted to evaluate inpatient DOAC dosing, and limited data regarding rationale for off-label dosing are available.
The objective of this study was to determine if adherence to FDA-approved dosing recommendations for apixaban is maintained in hospitalized patients with NVAF. We also aimed to describe which of the 3 clinical criteria (age ≥80 years, body weight ≤60 kg, or SCr ≥1.5 mg/dL) were met in patients receiving off-label dosing and to characterize the rationale for prescribing off-label apixaban doses.
Methods

Study Design and Population
This was a multicenter retrospective study conducted at 3 diverse hospitals: Medical City Arlington, a 342-bed community hospital; Mercy Hospital St Louis, a 979-bed teaching hospital; and University of South Alabama Medical Center, a 132-bed academic medical center. Patients were identified via the electronic medical records based on receipt of apixaban for the indication of atrial fibrillation or atrial flutter between September 1, 2014, and August 31, 2015.
Patients 18 years or older with a diagnosis of NVAF or atrial flutter who received at least 1 dose of apixaban during hospitalization were included. Patients were excluded if they were receiving apixaban for multiple indications. After identification of all patients meeting criteria for study inclusion, a significantly higher number of patients were identified at Mercy Hospital St Louis in comparison to other facilities being evaluated. In an effort to prevent overrepresentation from one study site, a systematic sampling strategy of including every other patient was implemented after patient randomization. Institutional review board approvals were obtained prior to data collection at all sites.
Outcomes
The primary outcome was to determine whether apixaban dosing in the inpatient setting aligns with FDA-approved dosing in NVAF. All dosing orders congruent with FDAapproved dosing were deemed appropriate. All off-label dosing orders were further specified as underdosed or overdosed. Secondary outcomes were to determine the extent at which pharmacist order verification increased the number of appropriate apixaban orders; to describe which, if any, of the 3 clinical criteria (age ≥80 years, body weight ≤60 kg, or SCr ≥1.5 mg/dL) were met in patients receiving off-label dosing, and to describe the rationale for prescribing offlabel apixaban doses. Rationale for off-label apixaban dosing included a history of gastrointestinal (GI) bleed, perceived high risk for bleeding, continuation of home dose, unspecified, dose entered in error, or other.
Safety outcomes of in-hospital bleeding and thrombosis were documented. Bleeding was classified as major, clinically relevant nonmajor, or minor bleeding. Major bleeding was defined by International Society on Thrombosis and Haemostasis criteria. 8 Clinically relevant nonmajor bleeding was defined as bleeding requiring hospitalization, physician intervention, or a change and/or discontinuation of apixaban therapy. All bleeding events not meeting the above criteria were deemed minor bleeds. Thrombosis was defined as stroke or venous thromboembolism, identified via physician diagnosis in the medical record.
Data Analysis
Inpatient apixaban orders were compared with FDAapproved dosing, both at the time of provider order entry and after pharmacist verification. Data from all 3 cohorts (appropriate, underdosed, overdosed) were analyzed in composite using descriptive statistics. Student's t test or Mann-Whitney U were used to compare continuous data as appropriate, and the χ 2 or Fisher exact test was used for categorical data. Logistic regression was performed to determine the impact of age, weight, and SCr on dosing category. A P value <0.05 indicates statistical significance. Analyses were performed by Statistical Analysis Software, 9.3 edition.
Results
A total of 556 apixaban orders were analyzed from Medical City Arlington (n = 198), Mercy Hospital St Louis (n = 310), and University of South Alabama Medical Center (n = 48). Baseline demographics are described in Table 1 . Out of the 556 orders, 420 (75.5%) were for the standarddose apixaban, and 136 (24.5%) were for reduced-dose apixaban. Apixaban was dosed with the approved labeling by providers in 464 (83.4%) of inpatient orders. After pharmacist review, 484 (87.0%) of apixaban orders were at the FDA-approved dose. A detailed account of all apixaban orders by provider and after pharmacist review can be found in Figures 1 and 2 . Overall, pharmacist order review resulted in a 3.6% increase in appropriately dosed apixaban orders.
After provider entry and pharmacist verification, 68 (12.2%) patients received a lower-than-recommended dose, and 4 (0.7%) patients received a higher-than-recommended dose. Compared with patients who received an FDAapproved dose of apixaban, patients who received an offlabel dose were significantly older (70.9 vs 78.3 years of age, respectively; P < 0.001) and weighed less (91.3 kg vs 76.3 kg, respectively; P < 0.001).
Of the 68 patients who were underdosed, 12% (n = 8) did not meet any criteria for dose reduction, and 88% (n = 60) met only 1 of 2 dose reduction criteria. The most common single dose reduction criterion met was age ≥80 years (n = 38, 56.0%), followed by SCr ≥1.5 mg/dL (n = 20, 29.0%), and weight ≤60 kg (n = 2, 3.0%). Rationale for underdosing included continuation of home dose (n = 26); perceived increased bleeding risk as deemed by the ordering provider (n = 18); history of GI bleed (n = 4); dosing error (n = 2) by the ordering provider or pharmacist, which was corrected later in the hospitalization; unspecified (n = 15); or other (n = 3) reason. Rationale for overdosing includes dosing error that was corrected later in the hospitalization (n = 2) and continuation of a home dose (n = 2). The combined rationale for divergence from FDA-approved dosing can be found in Figure 3 .
Logistic regression revealed that age (P = 0.002), weight (P = 0.002), and SCr (P = 0.011) were all independent predictors of off-label dosing. The odds for off-label dosing were increased with advanced age (odds ratio [OR] = 1.24; 95% CI = 1.09-1.42), increased SCr (OR = 1.09; 95% CI = 1.02-1.16), and decreased body weight (OR = 1.25; 95% CI = 1.08-1.45). This translates to an increase in off-label dosing of approximately 24% with every 5-year increase in age, 25% with every 10-kg decrease in weight, and 8% with every 0.3-mg/dL increase in SCr.
A total of 15 (2.7%) bleeding events were identified. Of these, 10 events (66.7%) occurred on the 5-mg BID dose (all appropriately dosed) and 5 (33.3%) occurred on the 2.5-mg BID dose (4 underdosed, 1 appropriate). There were 4 major bleeds (2 appropriate [5 mg BID], 2 underdosed [2.5 mg BID]), 
clinically relevant nonmajor bleeds (2 appropriate [5 mg BID], 2 underdosed [2.5 mg BID]), and 7 minor bleeds (all appropriate [six 5 mg BID, one 2.5 mg BID])
. Of the major bleeding events, 3 patients experienced a GI bleed requiring 2 or more units of whole blood or red cells, and 1 had a decrease in hemoglobin >2 g/dL, which was thought to be unrelated to apixaban. There was no difference in bleeding between the approved and off-label dosing groups (2.3% vs 5.6%; P = 0.116). No incident of thrombosis was seen.
Discussion
In our study, 87.0% of apixaban orders were dosed based on the approved labeling, indicating that adherence to the more complex dosing recommendations for apixaban is maintained in hospitalized patients. The bulk of appropriate orders were provider driven. Pharmacist review increased the number of orders at the approved dose; however, the increase was relatively small. These findings are consistent with those of other trials, which found 77% to 86% of apixaban orders being consistent with package insert recommendations. 7, 9 Age, SCr, and weight were all independent predictors of off-label dosing. Most off-label doses were for lower-thanrecommended doses. In the ORBIT-AF II trial, a study of 5738 patients that sought to determine the extent to which DOACs are dosed according to package insert recommendations in NVAF, the frequency of off-label dosing for apixaban was 11.8% for patients receiving doses lower and 2.1% for patients receiving doses higher than FDA-approved doses. 7 This is similar to our results of 12.2% and 0.7%, respectively. Although ORBIT-AF II investigated outpatient use of DOACs, the similar off-label dosing frequencies between ORBIT-AF II and our data suggest that similar prescribing barriers exist for dosing in both the inpatient and outpatient settings despite frequent weight and SCr monitoring in the inpatient sector.
Overall, the reduced-dose prescribing rate in our study was 24.5%, which is significantly higher than the 4.7% seen in ARISTOTLE (which excluded patients with a SCr >2.5 mg/dL) but similar to the 20.8% noted previously in a realworld population by Nguyen et al. 3, 4 Of those prescribed a reduced dose in our study, 50% were considered to be underdosed according to the FDA-approved dose reduction criteria. Barra et al 6 also found that 56.7% of dose reductions were not FDA indicated, although this result was representative of all DOACs and not specific to apixaban. In fact, when focusing specifically on the off-label dose reductions of apixaban for NVAF, the rate increases to 87.5%, a number that is likely enhanced because of the small number of apixaban orders (24 total orders). 6 Similar to our study, Barra et al 6 evaluated how many of the 3 clinical criteria were met for apixaban dose reduction in NVAF. In this study, only 12.5% of patients met 2 of 3 criteria, 54.2% met only 1 criterion, and 33.3% did not meet any of the criteria. 6 Again, application is limited by the small sample size; however, the majority of patients being underdosed were based on meeting only 1, rather than 2, criteria for dose reduction, which is consistent with our study. Rationale for divergence from FDA-approved dosing (includes both underdosing and overdosing; n = 72): increased bleeding risk is a composite of increased fall risk, thrombocytopenia, anemia, increased SCr, elderly status, and triple therapy (anticoagulation plus dual antiplatelet therapy) as defined by the ordering provider. Other is defined as currently meeting 1 of 2 dose reduction criteria but anticipated by provider to meet 2 of 2 in the near future (eg, weight loss, upcoming birthday).
Our study expands on these data by providing new information about which of the clinical criteria were met in patients who received an off-label dose reduction. Of 68 patients, 8 (12%) met none of the criteria, whereas the remaining 88% met 1 of 2 criteria. Age ≥80 years was the most common reason for underdosing (56%), followed by SCr ≥1.5 mg/dL (29%) and weight ≤60 kg (3%). These data suggest that in clinical practice, providers may consider advanced age the leading predictor of increased bleeding risk with apixaban, necessitating dose reduction. However, this has not been substantiated and does not meet FDArecommended dosage criteria. 2, 4 The most common rationale documented by providers for patients who received a lower-than-recommended dose was perceived high bleeding risk. This includes advanced age and perceived fall risk that often correlates with advanced age, further indicating that age appears to be the biggest barrier to appropriate prescribing. Other rationale for underdosing, both in our study and others, includes patients with a history of bleeding, concomitant use of medications known to increase bleeding risk, and moderate renal dysfunction. 6, 7 In addition to these factors, our study also identified continuation of a home dose (38.9% of patients) as another factor predictive of off-label apixaban prescribing. Uncertainty regarding the rationale for the original off-label dosing may lead to continuation of the apixaban dose during the transition from home to the inpatient setting. However, every opportunity to discover the reason for the off-label dosing and administer the FDAapproved dose should be seized.
Little clinical data are available to assess the benefits and risks of off-label dosing. Nielsen et al 10 found that dose reduction of apixaban resulted in a trend toward higher rates of stroke without any additional reductions in bleeding events compared with warfarin. Patients in this study were identified via prescription claims, and therefore, no direct assessment regarding the appropriateness of the dose reduction was able to be made. 10 In ORBIT-AF II, underdosing of DOACs was associated with increased incidence of cardiovascular hospitalization (adjusted hazards ratio [HR] = 1.26; 95% CI = 1.07-1.50), whereas overdosing was associated with an increased risk of all-cause mortality (adjusted HR = 1.91; 95% CI = 1.02-3.60). No differences were found in rates of first stroke, myocardial infarction, and major bleeding between off-label and FDA-approved dosing. 7 Our study also found no difference in major or overall bleeding between off-label and approved dosing. It should be noted, however, that our study was not powered to find a difference, and therefore, the chance of type II error exists. Still, these findings together support adherence to FDA-approved dosing in an effort to balance the benefits and risks associated with apixaban therapy.
To our knowledge, this is the first study to report adherence to FDA-approved dosing for apixaban in the inpatient setting. Strengths of this study include its multicenter design and investigation into real-world rationale for off-label dosing. Developing an understanding of factors that influence decisions to prescribe doses divergent from FDA recommendations is necessary to improve practice. Specifically, this study suggests that targeted education on the appropriate dosing of apixaban in patients ≥80 years of age without other criteria for dose reduction may be of benefit.
This study has several limitations. The retrospective study design imposes limitations on the ability to extract information from the chart regarding rationale for dose adjustments. Although provider rationale for off-label dosing could be discernible from the electronic medical record, the pharmacists' thought process during order verification was not readily available in documentation. Records of specific pharmacist intervention or documentation of conversation with providers would provide more in-depth insight into the reasons for off-label dosing. Furthermore, differences in documentation may have also occurred in the different hospital systems.
Conclusion
The majority of apixaban orders were based on FDAapproved dosages for NVAF. Off-label orders were composed primarily of lower-than-recommended doses. Divergence from FDA-approved doses occurred most commonly in patients who were ≥80 years old, received offlabel dosing prior to hospital admission, and were deemed to be at high risk for bleeding.
